Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents
NCT ID: NCT03062033
Last Updated: 2017-11-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
70 participants
OBSERVATIONAL
2017-04-04
2018-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1
Patients without visible signs of involuntary movements (possible TD) at time of clinician assessment
No interventions assigned to this group
Cohort 2
Patients with visible signs of involuntary movements (possible TD) at the time of clinician assessment
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient has a clinician confirmed diagnosis of one or more psychiatric disorder(s), as defined in the DSM-5
* Patient has a usual care clinic visit scheduled during the study recruitment window (i.e. a pre-defined 2-week period)
* Patient is able to read and understand English
* Patient is willing and able to comply with the study requirements
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Evidera
INDUSTRY
Neurocrine Biosciences
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chris O'Brien, MD
Role: STUDY_DIRECTOR
Chief Medical Officer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Neurocrine Clinical Site
Little Rock, Arkansas, United States
Neurocrine Clinical Site
Anaheim, California, United States
Neurocrine Clinical Site
Anaheim, California, United States
Neurocrine Clinical Site
Long Beach, California, United States
Neurocrine Clinical Site
Los Gatos, California, United States
Neurocrine Clinical Site
Oceanside, California, United States
Neurocrine Clinical Site
Gainesville, Florida, United States
Neurocrine Clinical Site
Hialeah, Florida, United States
Neurocrine Clinical Site
Jacksonville, Florida, United States
Neurocrine Clinical Site
Miami, Florida, United States
Neurocrine Clinical Site
Miami Beach, Florida, United States
Neurocrine Clinical Site
Miami Springs, Florida, United States
Neurocrine Clinical Site
North Miami, Florida, United States
Neurocrine Clinical Site
Orlando, Florida, United States
Neurocrine Clinical Site
Tampa, Florida, United States
Neurocrine Clinical Site
Decatur, Georgia, United States
Neurocrine Clinical Site
Honolulu, Hawaii, United States
Neurocrine Clinical Site
Naperville, Illinois, United States
Neurocrine Clinical Site
Michigan City, Indiana, United States
Neurocrine Clinical Site
Grand Rapids, Michigan, United States
Neurocrine Clinical Site
Rochester, Michigan, United States
Neurocrine Clinical Site
Kansas City, Missouri, United States
Neurocrine Clinical Site
St Louis, Missouri, United States
Neurocrine Clinical Site
Lincoln, Nebraska, United States
Neurocrine Clinical Site
Nashua, New Hampshire, United States
Neurocrine Clinical Site
Durham, North Carolina, United States
Neurocrine Clinical Site
Hickory, North Carolina, United States
Neurocrine Clinical Site
Garfield Heights, Ohio, United States
Neurocrine Clinical Site
Oklahoma City, Oklahoma, United States
Neurocrine Clinical Site
Houston, Texas, United States
Neurocrine Clinical Site
Houston, Texas, United States
Neurocrine Clinical Site
San Antonio, Texas, United States
Neurocrine Clinical Site
Salt Lake City, Utah, United States
Neurocrine Clinical Site
Bellevue, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EVA-19350
Identifier Type: -
Identifier Source: org_study_id